{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:26:13Z","timestamp":1758273973532,"version":"3.37.3"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clineuro.2024.108378","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T15:26:08Z","timestamp":1718465168000},"page":"108378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis"],"prefix":"10.1016","volume":"243","author":[{"given":"Minami","family":"Kanakura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-6782","authenticated-orcid":false,"given":"Makoto","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-956X","authenticated-orcid":false,"given":"Tomoyuki","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Beppu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Koda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori P.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichino","family":"Chinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6391-1933","authenticated-orcid":false,"given":"Tatsusada","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2024.108378_bib1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2024.108378_bib2","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51408","article-title":"DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France","volume":"8","author":"Sormani","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.clineuro.2024.108378_bib3","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001105","article-title":"COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context","volume":"9","author":"Sormani","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clineuro.2024.108378_bib4","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156978","article-title":"Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function","volume":"7","author":"Sabatino","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.clineuro.2024.108378_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ana.26251","article-title":"COVID-19 vaccine response in people with multiple sclerosis","volume":"91","author":"Tallantyre","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clineuro.2024.108378_bib6","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1212\/WNL.0b013e31820db341","article-title":"Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis","volume":"76","author":"Mehling","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2024.108378_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clineuro.2024.108378_bib8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2024.108378_bib9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.clineuro.2024.108378_bib10","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1007\/s00415-022-11030-0","article-title":"Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod","volume":"269","author":"Achiron","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2024.108378_bib11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jnnp-2022-330478","article-title":"Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunology","volume":"94","author":"Kihara","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2024.108378_bib12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.clineuro.2024.108378_bib13","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clineuro.2024.108378_bib14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.22426","article-title":"Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis","volume":"69","author":"Cohen","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clineuro.2024.108378_bib15","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000874","article-title":"Lymphocyte recovery after fingolimod discontinuation in patients with MS","volume":"7","author":"Nagy","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clineuro.2024.108378_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2015.03.022","article-title":"Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation","volume":"282","author":"Berger","year":"2015","journal-title":"J. Neuroimmunol."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724002658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724002658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:55:59Z","timestamp":1728370559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846724002658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":16,"alternative-id":["S0303846724002658"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108378","relation":{},"ISSN":["0303-8467"],"issn-type":[{"type":"print","value":"0303-8467"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108378"}}